Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.

Gary AltwergerEsther B FlorsheimGulden MenderesJonathan BlackCarlton SchwabGregory M GresselWendelin K NelsonNina CarusilloTerri PassanteGloria HuangBabak LitkouhiMasoud AzodiDan-Arin SilasiAlessandro SantinPeter E SchwartzElena S Ratner

Published in: Journal of cancer research and clinical oncology (2018)

We confirmed that gBRCA1/2 deficiency and advanced stage are independent risk factors for development of carboplatin hypersensitivity in ovarian cancer patients. Our study also shows improved OS in hypersensitive patients receiving CD compared to non-hypersensitive patients, independent of gBRCA1/2.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
phase ii study
drug induced
prognostic factors
squamous cell carcinoma
clinical trial
smoking cessation
rectal cancer